Browsing: exhibits

Diagnosis

Cemiplimab Exhibits Long-Term Clinical Benefit in Advanced NSCLC Trial

By NewsCancerApril 11, 20260

Miranda Gogishvili, MD, spoke with CancerNetwork® about the background and implications of a long-term analysis of findings from the phase…

Research

PIAS4 inhibition induces cell cycle arrest and exhibits a synergistic effect in combination with CDK4/6 inhibitor in breast cancer treatment

By NewsCancerApril 7, 20260

PIAS4 exhibits high expression levels in breast cancer and is inversely associated with prognosisComprehensive gene expression profiles of breast cancer…

Treatments

Mitomycin Exhibits Sustained 24-Month Survival in NMIBC Population

By NewsCancerMarch 30, 20260

Treatment with mitomycin (Zusduri) exhibited sustained event-free survival (EFS) among responders with low-grade intermediate-risk non-muscle invasive bladder cancer (NMIBC), according…

Survivors

Casdatifan Exhibits 1+ Year Survival in Later-Line Kidney Cancer

By NewsCancerFebruary 25, 20260

Later-line treatment with the HIF-2α inhibitor casdatifan exhibited progression-free survival (PFS) exceeding 1 year among patients with metastatic clear cell…

Research

Sortilin exhibits tumor suppressor-like activity by limiting EGFR transduction function

By NewsCancerFebruary 16, 20260

Sortilin and EGFR nuclear interaction in EGF-stimulated cellsBased on findings showing that sortilin limits EGFR proliferative signaling [18, 19], we…

What's Hot

Outlining Common Drawbacks to Prior Standards for Hodgkin Lymphoma

CD39/PD-L1 Inhibition May Improve pCR Rate in Resectable NSCLC

Cilta-Cel Produces Early Responses in Smoldering Multiple Myeloma

Browsing: exhibits

Cemiplimab Exhibits Long-Term Clinical Benefit in Advanced NSCLC Trial

PIAS4 inhibition induces cell cycle arrest and exhibits a synergistic effect in combination with CDK4/6 inhibitor in breast cancer treatment

Mitomycin Exhibits Sustained 24-Month Survival in NMIBC Population

Casdatifan Exhibits 1+ Year Survival in Later-Line Kidney Cancer

Sortilin exhibits tumor suppressor-like activity by limiting EGFR transduction function

Outlining Common Drawbacks to Prior Standards for Hodgkin Lymphoma

CD39/PD-L1 Inhibition May Improve pCR Rate in Resectable NSCLC

Cilta-Cel Produces Early Responses in Smoldering Multiple Myeloma

Epigenetic fingerprints link early-onset colon and rectal cancer to pesticide exposure

Outlining Common Drawbacks to Prior Standards for Hodgkin Lymphoma

CD39/PD-L1 Inhibition May Improve pCR Rate in Resectable NSCLC

Cilta-Cel Produces Early Responses in Smoldering Multiple Myeloma

Epigenetic fingerprints link early-onset colon and rectal cancer to pesticide exposure

Latest Post

Outlining Common Drawbacks to Prior Standards for Hodgkin Lymphoma

CD39/PD-L1 Inhibition May Improve pCR Rate in Resectable NSCLC

Cilta-Cel Produces Early Responses in Smoldering Multiple Myeloma

Subscribe to Updates

What's Hot

Browsing: exhibits